Integrating Novel Targets and Precision Medicine Into Prostate Cancer Care-Part 1: The Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer.

Integrating Novel Targets and Precision Medicine Into Prostate Cancer Care-Part 1: The Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer.

Publication date: Mar 13, 2019

Prostate cancer is the second most common cause of cancer-related death in men. Although the overall survival of patients with metastatic prostate cancer has improved with the addition of second-generation hormone therapy, most men will develop progressive disease, eventually leading to death. Novel therapeutic mechanisms are needed to improve treatments and outcomes in patients with metastatic prostate cancer. Biomarker-driven treatments such as targeted therapies and immuno-oncologic agents are currently under investigation, and may lead to less toxicity and better outcomes for these patients. Here, we review the current use and future direction of these novel therapeutic targets.

Considine, B. and Petrylak, D.P. Integrating Novel Targets and Precision Medicine Into Prostate Cancer Care-Part 1: The Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer. 04215. 2019 Oncology (Williston Park) (33):3.

Concepts Keywords
Biomarker Targeted therapy
Cancer Histopathology
Castration RTT
Hormone Therapy Clinical medicine
Lead Toxicity Prostate cancer
Metastatic Medicine
Progressive Hormone therapy
Prostate Cancer
Prostate Cancer Progressive disease
Targeted Therapies Cancer

Semantics

Type Source Name
drug DRUGBANK Tropicamide
gene UNIPROT ELL
disease MESH men
disease MESH death
disease DOID cancer
disease MESH cancer
pathway BSID Prostate cancer
disease DOID Prostate Cancer
disease MESH Prostate Cancer

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *